Outcome of board meeting and submission of unaudited financial Results for the quarter ended 30.06.2026

MPS PHARMAA LIMITED (FORMERLY ADVIK LABORATORIES LIMITED) Dated: 13t August, 2026 The Manager (Listing) BSE Limited 01stFloor, P.J. Towers Dalal Street, Mumbai - 400001 Sub: Outcome of the Board Meeting and Submission of Standalone Un-audited Financial Results for the quarter ended 30t June, 2026 as required u/r 33 of the SEBI (LODR) Regulations, 2015 Ref: BSE Scrip Code 531686; ASE Scrip Code- 01636 (ADVIK LABO) Dear Sir, This is to inform you that pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, the Board of Directors of the Company in its meeting held on Thursday, 13t August, 2026 at 12:00 P.M.at the corporate office of the company situated at 703, Arunachal Building, 19, Barakhamba Road, Connaught Place, New Delhi - 110001 and concluded at 02:20 P.M has inter-alia, transacted the following business: Considered and Approved the Standalone Un-audited Financial Results of the Company for quarter ended 30t June, 2026. Considered and Approved the Limited Review Report for the Standalone Un-audited Financial Results of the Company for quarter ended 30t June, 2026. Further pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, a copy of the aforesaid Standalone Un- audited Financial Results for the quarter ended 30t June, 2026 along with Limited Review Report thereon for quarter ended 30th June, 2026 is enclosed herewith for your kind perusal. Kindly take the aforesaid information in your records. Thanking You. Yours Truly, For MPS Pharmaa Limited (Formerly Advik Laboratories Limited) POOJA CHUNI gz iiess St Pooja Chuni Company Secretary Encl: As above The Manager (Listing) Ahmedabad Stock Exchange Limited 01st Floor, Kamdhenu Complex Opp. Sahajanand College, Panjara Pole, Ambawadi, Ahmedabad - 380015 CIN No. : L74899HR1994PLC038300 Corporate Office : 703, Arunachal building 19, Barakhamba Road, Connaught Place, New Delhi 110001 Phones: 011-42424884, 43571040-45, Fax: 011-43571047 Regd. Office & Factory: 138. Roz-Ka-Meo Industrial Area, Sohna - 122103 (Distt.Mewat), Haryana Phones: 0124-2362471 Email:info@mpspharmaa.comWebsite: www.mpspharmaa.com 7RAPSS MPS PHARMAA LIMITED( FORMERLY ADVIK LABORATORIES LIMITED) Regd. Off. :138, Roz Ka Meo Industrial Area, Sohna, Distt. Nuh, Haryana - 122103 STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 CIN : L74899HR1994PLC038300 (Rs in Lacs except EPS) SrNo_|Particulars Quarter ended Year Ended| 30-Jun-26] 31-Mar-26| 30-Jun-25| 31-Mar-26 (Unaudited) (Audited)] __ (Unaudited) (Audited)| Income from Operation (a) Net Sales/Revenue from Operations 1 [(b) Other Operating Income . (c) Other Income - 3.56 - 356 Total Income - 3.56 - 3.56 Expenses ) Cost of Materials consumed b) Purchase of Stock-in-trade ) Changes in Inventory of Finished goods, Work-in-progress and Stock-in-trade - - 2 [d) Employee Benefits Expenses 14.36 1384 13.16 5331 ) Finance Costs 0.06 003 001 008 ) Depreciation and Amortisation expense 3.51 367 367 14.68 8) Store & spares Written Off due to Deterioration - 15.37 1537 h) Other expenses 5.88 7.60 6.03 2591 Total Expenses 23.80 40.51 22.87 109.35 3 |Profit/(Loss) before Exceptional items and tax (1-2) (23.80) (36.95) (22.87)] (105.79)] 4 |Exceptional ltems B 2 3 B 5 |Profit/(Loss) before tax (3 + 4) (23.80)] (36.95)| (22.87)) (105.79) 6 |TaxExpense Current tax . . - Deferred tax 0.00 (1.02) (0.86) (3.79) -Adjustment of MAT Crediotf earlier years z 2 . Total Tax Expenses 0.00 (1.02)] (0.86) (3.79) 7__|profit/(Loss) for the period (5-6) (23.80) (35.93) (22.01) (102.00) 8 |Other CompreheInncosmei (vOCeI) items that will not be reclassified to Profit & Loss A/c T 0% 0.06 033 106 9 |Deferred Taxon OCI (0.07) (0.01) (0.09) (0.27) 10 |Total Comprehensive Income for the period ( 7+8-9) (23.61) (35.89) (21.76) (101.22) 11 [Paid-up equity share capital ( face value of Rs 10/- per share ) 1,911.14 1,911.14 1,911.14 1,911.14 12 [Earning per share (EPS) of Rs 10/- each (not annualized) (1) Basic (0.12) (0.19) (0.12) (053) (2) Diluted (0.12) ©19) (0.12) (053] NOTES: The above Financial Results for the quarter ended June 30, 2026 has been reviewed by the Audit Committee and thereafter 1 |approved by the Board of Directors & taken on record at its meeting held on August 13, 2026. A Limited review of the same has been carried out by the Statutory Auditors. , |e Company operates in a single segment viz pharmaceuticals formulations and the resulls pertain (0 a single segment i accordance with IND AS 108-Operating Segment. The company has applied for renewal of its Drug Manufacturing Licences before the term of its expiry with the Food & Drugs Administration (FDA), Panchkula, for manufacturing pharmaceutical and allied products and the same is under consideration at the end of the FDA. The management of the company firmly believes that the company would be able to restart its business 3 |operations as the company is getting quotes from the prospective buyers & the management is of the pinion that the new deals would be finalized soon. Further, the management of the company is also exploring the market and business opportunities and is putting necessary efforts in this respect so that the operations of the company can be started again. 4 |The Figures for the quarter ended March 37, 2026 represents the balancing Figures between the audiled figures for fhe ful financial years and the published figures for the 9 months ended December 31, 2025 respectively Page 1 of 2 Auditor's Observations in Audit Report for the Financial year 2025-26 as updated as on 30.06.2026 a) The company had recorded the cost of the investment of Rs. 53.80 Lac at the cost of Acquisition value of the equity shares issued and had not determined the fair value as required by Ind AS. The shares were not made available for physical verification Hence, we are unable to comment upon the physical existence and express an opinion on the value of investment recorded ©) The Capital work in Progress of Rs. 2.12 Crore has been stalled. The physical conditions of these assets under construction require technical evaluation to determine impairments or write offs, if any. However in view of the management the suspension is temporary in nature and assets under construction are not obsolete, and the company will be able to resume construction activities in near future and accordingly no provision is required Our explanation to Auditor's Observation:- a. The company has misplaced/lost the share certificates of the investments made by it in unquoted equity shares of other| companies during the shifting of its records. Hence the company is unable to locate its investments made in the unquoted equity shares as the same are not physically held by the company at present. Despile sending multiple requests to the companies in which it has made investments for issue of duplicate share certificates, the same have not yet been entertained and till date the| company has not received any reply from these companies. In addition to this, the company is working towards determining the fair market value of its investments to ensure the compliance with IND AS in true letter and spirits b. The company allocated funds for building an additional factory block & for Godown fo expand its operations. bul due (o] technical and other reasons, construction had to be temporarily suspended. Management believes the suspension is temporary and the under-construction assets are not obsolete. The company anticipates resuming construction activities soon and does not foresee the need for any provisions. Additionally, the company is receiving advances back from some vendors due to non execution of deals. The Company has not paid the Annual Listing Fees (ALF) of the Bombay Stock Exchange Limited (BSE) since the financial year| 2021-22. Consequently, BSE has initiated action against the Company and suspended trading of its scrip on the Exchange's| trading platform. However, BSE has permitted trading in the Company's shares on a Trade-for-Trade bas [Showing first 8,000 characters — download PDF for full document]